The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed New Long Term Incentive Plan

11 Oct 2010 16:00

RNS Number : 2047U
PuriCore Plc
11 October 2010
 



PuriCore plc  

Proposed New Long Term Incentive Plan and Proposed Amendment to the Existing Option Plan and Notice of General Meeting

 

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 11 October 2010 - PuriCore plc (LSE: PURI) ("PuriCore" or the "Company"), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces that it is proposing a new Long Term Incentive Plan ("LTIP") and an amendment to the Company's Executive Omnibus Incentive Plan (the "Option Plan").

 

A circular is expected to be posted today to Shareholders by the Company that contains details of the LTIP and the associated proposed change to the Option Plan (the "Circular"). The Directors are seeking approval of the LTIP and the amendment to the Option Plan at a General Meeting to be held at 9.00 a.m. at the offices of CMS Cameron McKenna LLP, Mitre House, 160 Aldersgate Street, London EC1A 4DD on 29 October 2010.

 

PuriCore Value Sharing Plan (LTIP)

The LTIP allows the creation of an award pool of 15% of the amount by which the market capitalisation of the Company exceeds £35 million on 30 September 2012. This award pool will be allocated amongst the participants at a pre-determined rate and is intended to be satisfied through a combination of new ordinary shares and cash. To implement the LTIP, the Option Plan is proposed to be amended to exclude the issue of any share awards under the LTIP from the Option Plan dilution limit.

 

PuriCore will realise short-term cash savings from the implementation of the LTIP as some participants are accepting reductions in cash-based compensation-for the term of the LTIP-in exchange for participation in the LTIP. These reductions include foregoing employer retirement plan contributions and waiving rights to the annual bonus scheme, for those participants who are entitled to these benefits, and certain participants taking an approximate 17% reduction in basic salary. Further, all participants must waive their rights to existing share option grants, whether vested or unvested.

 

A summary of the LTIP and a summary of the proposed amendment to the Option Plan is set out in the Circular.

 

Background to the PuriCore Value Sharing Plan

The Remuneration Committee of the Board of Directors (the "Remuneration Committee") believes the LTIP is an appropriate tool to motivate the participants to achieve the Company's sales growth and profitability goals, and to deliver significant value to shareholders in terms of market capitalisation increase. The Remuneration Committee is confident that the senior executive team charged with delivering the Company's goals is focused and that the strategies being implemented should allow the Company to meet its goals on an accelerated basis. Aligning the senior executive remuneration strategy with the Company's business goals and with the interests of shareholders is critical. The Remuneration Committee believes the LTIP does this in the following ways:

 

·; incentivises the participants to focus on strategies and tactics with a common goal of creating shareholder wealth by increasing market capitalisation;

 

·; establishes a challenging market capitalisation hurdle of £35 million (compared with the current market capitalisation of approximately £13 million) below which participants receive no pay-out;

 

·; provides a short-term (24-month) period for delivering on the Company's goals; and

 

·; offers flexibility in the type of senior executive remuneration (shares or cash), which the Remuneration Committee can utilise based on the financial and cash position of the Company at the time of the award.

 

A copy of the Circular and related form of proxy have been submitted to the National Storage Mechanism and will shortly be available for inspection. The Notice of General Meeting will shortly be available on the Company's website.

 

Enquiries:

 

Financial Dynamics

PuriCore

Susan Quigley

Chris Wightman

Ben Brewerton

Executive Chairman

+44 (0) 20 7831 3113

+44 (0) 20 7290 3440

 

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEALEFFSEEFFF
Date   Source Headline
9th Oct 20185:02 pmRNSForm 8.3 - Realm Therapeutics PLC
9th Oct 201810:13 amRNSForm 8.3 - Realm Therapeutics plc
5th Oct 20186:08 pmBUSForm 8.3 - Realm Therapeutics PLC
5th Oct 20182:00 pmRNSFORM 8.3 - Realm Therapeutics Plc
4th Oct 20188:57 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics plc
2nd Oct 201810:43 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics PLC
1st Oct 20187:00 amRNSProvides Update on Timing of Formal Sale Process
24th Sep 20189:59 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Sep 201811:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20183:16 pmRNSHolding(s) in Company
20th Sep 201811:53 amRNSForm 8.3 - REALM THERAPEUTICS PLC
20th Sep 201811:18 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Sep 20184:31 pmRNSForm 8 (OPD) - Realm Therapeutics plc
19th Sep 201811:11 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
18th Sep 201811:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
17th Sep 20187:00 amRNSCorporate Update and Hiring of Advisor
20th Aug 201811:00 amRNSPrice Monitoring Extension
20th Aug 20187:00 amRNSBlock listing Interim Review
15th Aug 20184:35 pmRNSPrice Monitoring Extension
14th Aug 20187:10 amRNSHalf-year Report
8th Aug 20187:00 amRNSPresents at Wedbush PacGrow Healthcare Conference
7th Aug 20187:00 amRNSNotice of Results
16th Jul 20185:33 pmRNSHolding(s) in Company
10th Jul 20187:00 amRNSPre-Clinical Study in Atopic Dermatitis
4th Jul 20187:00 amRNSInstructions for Exchanging Ordinary Shares
4th Jul 20187:00 amRNSSEC registration effective NASDAQ listing approved
14th Jun 201810:54 amRNSResult of AGM
31st May 20187:00 amRNSRealm to Present at June Investor Conferences
24th May 20187:00 amRNSEnrollment complete for Phase 2 study of PR022
23rd May 20187:00 amRNSFiling with US SEC to Facilitate Nasdaq Listing
21st May 20187:00 amRNSData Presentation at IID 2018
2nd May 201812:39 pmRNSAnnual Financial Report Available
2nd May 20187:00 amRNSFinal Results
2nd May 20187:00 amRNSRealm Files Registration for Nasdaq Listing of ADS
26th Apr 20182:32 pmRNSNotice of Results
12th Mar 20184:40 pmRNSSecond Price Monitoring Extn
12th Mar 20184:35 pmRNSPrice Monitoring Extension
12th Mar 20187:00 amRNSClinical Update including PR013 Phase II results
8th Mar 20187:00 amRNSPresenting at Cowen Healthcare Conference
27th Feb 20187:00 amRNSPatent portfolio strengthened with USPTO allowance
20th Feb 201812:00 pmRNSPresentation at RBC Healthcare Conference
16th Feb 20187:00 amRNSBlock listing Interim Review
15th Feb 20187:00 amRNSClinical and Business Update
2nd Jan 20187:00 amRNSPresents at 5th Annual Dermatology Summit
15th Dec 20177:00 amRNSDirector/PDMR Shareholding
12th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR013
5th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.